MAO-B inhibitor plus dopamine agonist combination

This page covers all MAO-B inhibitor plus dopamine agonist combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Monoamine oxidase B and dopamine D2/D3 receptors.

Targets

Monoamine oxidase B and dopamine D2/D3 receptors

Marketed (1)

• Rasagiline mesylate plus Mirapex · Teva Neuroscience, Inc. · Neurology
  This combination pairs a monoamine oxidase B inhibitor with a dopamine agonist to enhance dopaminergic signaling in the brain for Parkinson's disease management.

Patent intelligence

• mao b inhibitor plus dopamine agonist combination patent landscape — aggregated cliff calendar, attackable patents, originator estates